Last week, Representatives John Curtis (UT-03) and Paul Tonko (NY-20) introduced the Pediatric Research Site Network Act, legislation designed to empower the Food and Drug Administration (FDA) to collaborate with organizations in the scientific and academia to close gaps within pediatric clinical trials.
“Accurate and clear labeling is vital for pediatric medicine,” said Rep. Curtis. “Utah has one of the nation’s highest population of children at 28% and this legislation will foster collaboration between science and academia to address gaps in pediatric clinical trials, ensuring accurate testing, better labeling, and safer medicines for them.”
In the 1990s, the Food and Drug Administration and Congress collectively recognized a critical insufficiency in pediatric populations when it came to the labeling and approval of therapeutic treatments. This realization spurred a series of impactful legislative measures including the Pediatric Rule of 1998, the Best Pharmaceuticals for Children Act (BPCA) of 2002, and the Pediatric Research Equity Act (PREA) of 2003. These pivotal laws have been instrumental in encouraging pharmaceutical enterprises to prioritize the development of medicines tailored for children.
Notwithstanding these advancements, the efficacy of pediatric clinical drug development strategies continues to be marred by inefficiencies, delay, and exorbitant costs. Consequently, children often endure a decade-long or longer wait to gain access to medications initially authorized for adult use.
These challenges have manifested in prolonged startup periods for pediatric trials, often double or triple that of adult clinical trials. Worse still, a staggering 60 percent of these trials stall and nearly 40 percent result in failure.
This legislation would empower the FDA to form collaborative agreements with reputable organizations within the scientific community and academia. By doing so, these partnerships aim to eradicate present-day inadequacies surrounding pediatric clinical trials.
BACKGROUND:
The proposed legislation outlines a series of strategic steps that will enable the following:
- Development and Maintenance of Pediatric Research Site Network: A dedicated network focused on pediatric clinical trials, geared towards bolstering regulatory approvals and informed labeling decisions.
- Guidance on Study Design and Feasibility: Offering comprehensive guidance to streamline pediatric study design and feasibility assessments. This provision serves to identify and address challenges faced by research sites, thus reducing delays that impede pediatric clinical trials.
- Educational Resources on Best Practices: Providing educational resources that illuminate pivotal changes and best practices within the realm of pediatric clinical trials.
- Quality Improvement Initiatives: Implementing a quality improvement program that enhances processes across all network sites engaged in pediatric research.
